On September 9, 2022, the U.S. Food and Drug Administration (FDA) approved eflapegrastim-xnst to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies who are receiving myelosuppressive treatment.
For more information, read the Spectrum Pharmaceuticals announcement.
Posted 9/12/2022
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
